Impurity Profile Influence in Pharmaceutical Intermediate Synthesis is recognized within pharmaceutical chemistry for its critical role in defining the purity and overall quality of intermediates central to drug development. Identified by its CAS number {cas_number}, this compound is described by the molecular formula {molecular_formula} and a molecular weight of {molecular_weight}. For precise chemical identification, the IUPAC name is {iupac_name}, while the InChIKey {inchikey} enables unambiguous registry searching and analytical traceability. This material is commonly classified as a pharmaceutical intermediate, underlining its value within multi-step synthesis routes leading to active pharmaceutical ingredients.
Detailed specifications of Impurity Profile Influence in Pharmaceutical Intermediate Synthesis provide insight into its performance characteristics and handling considerations. The compound’s physical properties, such as {boiling_point}, {melting_point}, {density}, {flash_point}, and {vapor_pressure}, set definitive operational parameters for those working at scale in chemical process environments. Such specifications are pivotal for risk assessment and optimal process design.
From a regulatory and compliance standpoint, Impurity Profile Influence in Pharmaceutical Intermediate Synthesis conforms to rigorous international standards. Its REACH status, if registered, is described with the corresponding article number and tonnage band, ensuring that European supply chain partners have transparency regarding environmental and health safety obligations. If this substance is listed on the United States TSCA inventory, the precise section reference specifies its authorized handling. Relevant ICH guidance—quoted with full code and revision—defines acceptable impurity limits, demonstrating alignment with evolving pharmaceutical quality expectations. Where applicable, its GHS hazard classification is provided with each associated H-phrase and signal word, allowing safe management and transport globally. Pharmacopeia references with explicit chapter numbers further demonstrate the material’s benchmark status within official compendia. Occupational safety data, such as OSHA PEL and NIOSH REL, may be included as available to facilitate safe work practices.
Applications for Impurity Profile Influence in Pharmaceutical Intermediate Synthesis primarily center on its function as a process intermediate in the manufacturing of medicinal products. Its impurity profile is closely scrutinized for potential impact on the critical quality attributes of final active pharmaceuticals. For those involved in route design or process optimization, this compound may be encountered in the synthesis of various small molecule drugs. Any further detail regarding use in specific drug syntheses is determined by its placement in established or proprietary synthetic pathways, reflecting the continual innovation in modern medicinal chemistry.
Standard packaging for this intermediate typically includes 25-kilogram fiber drums, 200-kilogram steel drums, and intermediate bulk containers, all of which support flexibility in both smaller and larger scale operations. Recommended storage conditions conform to GHS stability profiles, generally entailing storage in a tightly sealed container, away from incompatible substances, protected from excessive heat and moisture, and in a well-ventilated space. Shelf life for this class of intermediates is generally guided by industry best practices, often ranging from two to five years under controlled storage with regular inspection of the container’s integrity and material appearance.
References for further scientific, safety, and regulatory insights include PubChem, NIST’s Chemistry WebBook, the ECHA portal, and the EPA TSCA Inventory, providing authoritative information for researchers, regulatory professionals, and purchasing managers alike.
Related Articles
